Skip to main content
Premium Trial:

Request an Annual Quote

Another Fraud Charge

Prosecutors have added a twelfth fraud charge against former Theranos CEO Elizabeth Holmes, the Mercury News reports.

Theranos, which was once valued at $9 billion, ran into trouble after a series of Wall Street Journal articles raised questions about its technology and ability to run diagnostic tests on a finger-prick's worth of blood. An investigation by US regulators uncovered a number of questionable lab practices at the firm, which led to Holmes and Ramesh 'Sunny' Balwani, the company's president, being barred in 2016 from owning or operating any lab for two years.

Theranos eventually shuttered its labs in 2016 and closed in 2018.

Also in 2018, Holmes and Balwani were indicted on nine charges of wire fraud and two charges of conspiracy to commit wire fraud. Prosecutors allege Holmes and Balwani defrauded investors and doctors as they knew Theranos could not run tests as claimed. Both pleaded not guilty, and Holmes' trial was scheduled to begin this August, but the ongoing COVID-19 pandemic has pushed her trial back to at least late October, as CNBC reported last month.

According to the Mercury News, a new fraud charge was filed in the case relating to a patient's testing results.

The Scan

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.

Duke University Team Develops Programmable RNA Tool for Cell Editing

Researchers have developed an RNA-based editing tool that can target specific cells, as they describe in Nature.

Novel Gene Editing Approach for Treating Cystic Fibrosis

Researchers in Science Advances report on their development of a non-nuclease-based gene editing approach they hope to apply to treat cystic fibrosis.

Study Tracks Responses in Patients Pursuing Polygenic Risk Score Profiling

Using interviews, researchers in the European Journal of Human Genetics qualitatively assess individuals' motivations for, and experiences with, direct-to-consumer polygenic risk score testing.